Cited by 119Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchCholinesterase and Neurodegenerative Diseases

The DOI matches its Crossref record; 248 of the 250 references it cites were found in a registry or an index.

Disease modifying therapy for AD?1

Open access

Golde, Todd E.·2006·Journal of Neurochemistry

DOI 10.1111/j.1471-4159.2006.04211.x

Open this paper in CoChat — free account Open PDF

Abstract

Alzheimer's disease (AD) is the most common form of dementia in industrialized nations. If more effective therapies are not developed that either prevent AD or block progression of the disease in its very early stages, the economic and societal cost of caring for AD patients will be devastating. Only two types of drugs are currently approved for the treatment of AD: inhibitors of acetyl cholinesterase, which symptomatically enhance cognitive state to some degree but are not disease modifying; and the adamantane derivative, memantine. Memantine preferentially blocks excessive NMDA receptor activity without disrupting normal receptor activity and is thought to be a neuroprotective agent that blocks excitotoxicty. Memantine therefore may have a potentially disease modifying effect in multiple neurodegenerative conditions. An improved understanding of the pathogeneses of AD has now led to the identification of numerous therapeutic targets designed to alter amyloid beta protein (Abeta) or tau accumulation. Therapies that alter Abeta and tau through these various targets are likely to have significant disease modifying effects. Many of these targets have been validated in proof of concept studies in preclinical animal models, and some potentially disease modifying therapies targeting Abeta or tau are being tested in the clinic. This review will highlight both the promise of and the obstacles to developing such disease modifying AD therapies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1111/j.1471-4159.2006.04211.x

Cites

248 of 248 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Alzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Amyloid plaque core protein in Alzheimer disease and Down syndrome.
Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431
β-Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE
Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876 · cited 1×
“…membrane bound aspartyl protease responsible for b-secretase cleavage of APP (BACE, memapsin, b-secretase) (Hussain et al. 1999; Sinha et al. 1999; Vassar et al. 1999; Yan et al. 1999). b-secretase is an excellent theoretical target as it is the rate limiting enzyme in Ab production, but it has…”
Background
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Neurodegenerative Tauopathies
Lee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480

Show all 250 references

Research works printed but not linked: 2

Black S., 2006, Efficacy and safety ofMPC‐7869 (R.‐flurbiprofen), a selective Abeta42 loering agent in mild Alzheimer's disease: results of a 12‐month phase 2 trial and 1‐year follow on study, Neurology, 66, A347
Seabrook T. J., 2006, Dendrimeric Abeta1–15 is an effective immunogen in wildtype and APP‐tg mice, Neurobiol. Aging.

Sorted by citations

Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse
Parsons, C. G., Stöffler, A., & Danysz, W. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.07.013 · Cited by 724
Hyperphosphorylation of Microtubule-Associated Protein Tau: A Promising Therapeutic Target for Alzheimer Disease
Gong, C., & Iqbal, K. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708785909111 · Cited by 672
Recent advances in the multitarget‐directed ligands approach for the treatment of Alzheimer's disease
Leon, R. M., García, A. G., & Marco, J. L. (2011) · Medicinal Research Reviews · doi:10.1002/med.20248 · Cited by 447
Common pathological processes in Alzheimer disease and type 2 diabetes: A review
Li, L., & Hölscher, C. (2007) · Brain Research Reviews · doi:10.1016/j.brainresrev.2007.09.001 · Cited by 367
Overexpression of Low-Density Lipoprotein Receptor in the Brain Markedly Inhibits Amyloid Deposition and Increases Extracellular Aβ Clearance
Kim, J., Castellano, J. M., Jiang, H., Basak, J. M., Parsadanian, M., Pham, V., Mason, S. M., Paul, S. M., & Holtzman, D. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.11.013 · Cited by 274
Alzheimer's disease; a review of the pathophysiological basis and therapeutic interventions
Abeysinghe, A. A. D. T., Deshapriya, S., & Udawatte, C. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117996 · Cited by 259
Acute stress increases interstitial fluid amyloid-β via corticotropin-releasing factor and neuronal activity
Kang, J.-E., Cirrito, J. R., Dong, H., Csernansky, J. G., & Holtzman, D. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700148104 · Cited by 219
Neuroprotective properties of resveratrol and derivatives
Richard, T., Pawlus, A. D., Iglésias, M., Pédrot, E., Waffo‐Téguo, P., Mérillon, J., & Monti, J. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05865.x · Cited by 210
Tau oligomers and aggregation in Alzheimer’s disease
Meraz‐Ríos, M. A., León, K. I. L.-D., Campos‐Peña, V., Anda-Hernández, M. A. D., & Mena‐López, R. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06511.x · Cited by 193
Functional imaging studies of episodic memory in Alzheimer's disease: a quantitative meta-analysis
Schwindt, G., & Black, S. E. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2008.11.024 · Cited by 179
Alzheimer disease pathology as a host response
Castellani, R. J., Lee, H.-G., Zhu, X., Perry, G., & Smith, M. A. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318177eaf4 · Cited by 171
Update on the Pharmacological Treatment of Alzheimers Disease
Massoud, F., & Gauthier, S. G. (2010) · Current Neuropharmacology · doi:10.2174/157015910790909520 · Cited by 168
Amyloid-β immunisation for Alzheimer's disease
Wisniewski, T., & Konietzko, U. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70170-4 · Cited by 155
GSK-3 Inhibitors: A Ray of Hope for the Treatment of Alzheimer's Disease?
Martı́nez, A., & Pérez, D. I. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-15204 · Cited by 124
Versatility of the Curcumin Scaffold: Discovery of Potent and Balanced Dual BACE-1 and GSK-3β Inhibitors
Martino, R. M. C. D., Simone, A. D., Andrisano, V., Bisignano, P., Bisi, A., Gobbi, S., Rampa, A., Fato, R., Bergamini, C., Pérez, D. I., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00894 · Cited by 124
Memoquin: A Multi-Target–Directed Ligand as an Innovative Therapeutic Opportunity for Alzheimer's Disease
Bolognesi, M. L., Cavalli, A., & Melchiorre, C. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.10.042 · Cited by 117
Tetracycline and its analogues protect Caenorhabditis elegans from β amyloid-induced toxicity by targeting oligomers
Diomede, L., Cassata, G., Fiordaliso, F., Salio, M., Ami, D., Natalello, A., Doglia, S. M., Luigi, A. D., & Salmona, M. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.07.002 · Cited by 114
Novel insights for the treatment of Alzheimer's disease
Kurz, A., & Perneczky, R. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.07.018 · Cited by 115
Polysaccharides from Wolfberry Antagonizes Glutamate Excitotoxicity in Rat Cortical Neurons
Ho, J. Y. S., Yu, M. S., Yik, S.-Y., So, K., Yuen, W. H., & Chang, R. C. (2009) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-009-9419-x · Cited by 111
Oxidative Stress in Alzheimer’s Disease: Should We Keep Trying Antioxidant Therapies?
Ferreira, M. E. S., de Vasconcelos, A. S., Vilhena, T. D. C., da Silva, T. L., Barbosa, A. D. S., Gomes, A. R. Q., Dolabela, M. F., & Percário, S. (2015) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-015-0157-y · Cited by 111
Effects of Hypoxia and Oxidative Stress on Expression of Neprilysin in Human Neuroblastoma Cells and Rat Cortical Neurones and Astrocytes
Fisk, L., Nalivaeva, N. N., Boyle, J. P., Peers, C., & Turner, A. J. (2007) · Neurochemical Research · doi:10.1007/s11064-007-9349-2 · Cited by 106
Proteinopathy-induced neuronal senescence: a hypothesis for brain failure in Alzheimer’s and other neurodegenerative diseases
Golde, T. E., & Miller, V. M. (2009) · Alzheimer's Research & Therapy · doi:10.1186/alzrt5 · Cited by 98
Self-citation
Alois Alzheimer and Alzheimer's disease: a centennial perspective
Small, D. H., & Cappai, R. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04212.x · Cited by 102
Protective effect of the phosphodiesterase III inhibitor cilostazol on amyloid β-induced cognitive deficits associated with decreased amyloid β accumulation
Park, S. H., Kim, J. H., Bae, S. S., Hong, K. W., Lee, D., Leem, J. Y., Choi, B. T., & Shin, H. K. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.04.068 · Cited by 96
Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies
Buccellato, F. R., D’Anca, M., Tartaglia, G. M., Del Fabbro, M., Scarpini, E., & Galimberti, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813900 · Cited by 94
“…strategies beyond symptomatic medications have relied on (a) anti-A β production and aggregation agents, decreasing the synthesis of A β , such as β - and γ -secretase; (b) neutralizing or removing the toxic aggregate or misfolded forms of A β by immunotherapy; (c) anti-tau protein drugs [33,34].”
Background
Targeting Aβ and tau in Alzheimer's disease, an early interim report
Golde, T. E., Petrucelli, L., & Lewis, J. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.07.035 · Cited by 89
Self-citation
Protective effect of ε-viniferin on β-amyloid peptide aggregation investigated by electrospray ionization mass spectrometry
Richard, T., Poupard, P., Nassra, M., Papastamoulis, Y., Iglésias, M., Krisa, S., Waffo‐Téguo, P., Mérillon, J., & Monti, J. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.04.001 · Cited by 88
Network dysfunction in Alzheimer's disease: does synaptic scaling drive disease progression?
Small, D. H. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.12.006 · Cited by 83
New stilbene dimers against amyloid fibril formation
Rivière, C., Papastamoulis, Y., Fortin, P., Delchier, N., Andriamanarivo, S., Waffo‐Téguo, P., Kapche, G. D. W. F., Amira-Guebailia, H., Delaunay, J.-C., Mérillon, J., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.09.074 · Cited by 82
The Role of Aβ-Induced Calcium Dysregulation in the Pathogenesis of Alzheimer's Disease
Small, D. H., Gasperini, R., Vincent, A. J., Hung, A. C., & Foa, L. C. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-0951 · Cited by 77
Independent Generation of Aβ42 and Aβ38 Peptide Species by γ-Secretase
Czirr, E., Cottrell, B. A., Leuchtenberger, S., Kukar, T. L., Ladd, T. B., Esselmann, H., Paul, S., Schubenel, R., Torpey, J. W., Pietrzik, C. U., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802912200 · Cited by 72
Self-citation
Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575
Garcı́a-Alloza, M., Subramanian, M., Thyssen, D. H., Borrelli, L. A., Fauq, A. H., Das, P., Golde, T. E., Hyman, B. T., & Bacskai, B. J. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-19 · Cited by 71
Self-citation
A multigram chemical synthesis of the γ-secretase inhibitor LY411575 and its diastereoisomers
Fauq, A. H., Simpson, K. H., Maharvi, G. M., Golde, T. E., & Das, P. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.07.062 · Cited by 72
Self-citation
Neurodegenerative Disorders and Nanoformulated Drug Development
Nowacek, A. S., Kosloski, L. M., & Gendelman, H. E. (2009) · Nanomedicine · doi:10.2217/nnm.09.37 · Cited by 69
Does Vitamin D Reduce the Risk of Dementia?
Grant, W. B. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1024 · Cited by 67
The Quest for Small Molecules as Amyloid Inhibiting Therapies for Alzheimer's Disease
Amijee, H., & Scopes, D. I. C. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1044 · Cited by 65
The Polyphenol Piceid Destabilizes Preformed Amyloid Fibrils and Oligomers In Vitro: Hypothesis on Possible Molecular Mechanisms
Rivière, C., Delaunay, J.-C., Immel, F., Cullin, C., & Monti, J. (2008) · Neurochemical Research · doi:10.1007/s11064-008-9883-6 · Cited by 63
Fullerenolates: metallated polyhydroxylated fullerenes with potent anti-amyloid activity
Bobylev, A. G., Kornev, A. B., Bobyleva, L. G., Shpagina, M. D., Fadeeva, I. S., Фадеев, Р. С., Deryabin, D. G., Balzarini, J. M., Troshin, P. A., & Podlubnaya, Z. A. (2011) · Organic & Biomolecular Chemistry · doi:10.1039/c1ob05067b · Cited by 59
Water-soluble ginseng oligosaccharides protect against scopolamine-induced cognitive impairment by functioning as an antineuroinflammatory agent
Xu, T., Shen, X., Yu, H., Sun, L., Lin, W., & Zhang, C.-X. (2015) · Journal of Ginseng Research · doi:10.1016/j.jgr.2015.07.007 · Cited by 58
Promising anti-Alzheimer’s dimer bis(7)-tacrine reduces β-amyloid generation by directly inhibiting BACE-1 activity
Fu, H., Li, W., Luo, J., Lee, N. T. K., Li, M., Tsim, K. W. K., Pang, Y., Youdim, M. B. H., & Han, Y. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.11.068 · Cited by 56
An overview on therapeutics attenuating amyloid β level in Alzheimer's disease: targeting neurotransmission, inflammation, oxidative stress and enhanced cholesterol levels.
Zhou, X., Li, Y., Shi, X., & Ma, C. (2016) · PubMed · Cited by 56
Curcumin: a natural substance with potential efficacy in Alzheimer’s disease
Potter, P. E. (2013) · Journal of Experimental Pharmacology · doi:10.2147/jep.s26803 · Cited by 51
Glucagon-like peptide 1 and glucose-dependent insulinotropic peptide hormones and novel receptor agonists protect synapses in Alzheimer’s and Parkinson’s diseases
Hölscher, C. (2022) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2022.955258 · Cited by 49
Alzheimer's Disease: Another Target for Heparin Therapy
Bergamaschini, L. C., Rossi, E., Vergani, C., & Simoni, M. G. D. (2009) · The Scientific World JOURNAL · doi:10.1100/tsw.2009.100 · Cited by 46
The Validity of the Rowland Universal Dementia Assessment Scale (RUDAS) in a Multicultural Cohort of Community-dwelling Older Persons With Early Dementia
Basic, D., Rowland, J. T. J., Conforti, D. A., Vrantsidis, F., Hill, K., LoGiudice, D., Harry, J., Lucero, K., & Prowse, R. J. (2009) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31818ecc98 · Cited by 47
Association of Neuropathological Markers in the Parietal Cortex With Antemortem Cognitive Function in Persons With Mild Cognitive Impairment and Alzheimer Disease
Tremblay, C., François, A., Delay, C., Freland, L., Vandal, M., Bennett, D. A., & Calon, F. (2017) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlw109 · Cited by 49
Ac-LVFFARK-NH 2 conjugation to β-cyclodextrin exhibits significantly enhanced performance on inhibiting amyloid β-protein fibrillogenesis and cytotoxicity
Zhang, H., Dong, X., Liu, F., Zheng, J., & Sun, Y. P. (2018) · Biophysical Chemistry · doi:10.1016/j.bpc.2018.02.002 · Cited by 47
A role for 12/15 lipoxygenase in the amyloid β precursor protein metabolism
Succol, F., & Praticò, D. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04742.x · Cited by 41
Modulation of Microglial Innate Immunity in Alzheimers Disease by Activation of Peroxisome Proliferator-activated Receptor Gamma
Shie, F., Nivison, M. P., Hsu, P.-C., & Montine, T. J. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709787458399 · Cited by 41
Therapeutic approaches for prion and Alzheimer's diseases
Wısnıewskı, T., & Sigurdsson, E. M. (2007) · FEBS Journal · doi:10.1111/j.1742-4658.2007.05919.x · Cited by 41
Interaction of Alzheimer’s Aβ Peptide with an Engineered Binding Protein—Thermodynamics and Kinetics of Coupled Folding–Binding
Hoyer, W., & Härd, T. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.02.040 · Cited by 40
Rowland Universal Dementia Assessment Scale, Mini-Mental State Examination and General Practitioner Assessment of Cognition in a multicultural cohort of community-dwelling older persons with early dementia
Basic, D., Khoo, A., Conforti, D. A., Rowland, J. T. J., Vrantsidis, F., LoGiudice, D., Hill, K., Harry, J., Lucero, K., & Prowse, R. J. (2009) · Australian Psychologist · doi:10.1080/00050060802593593 · Cited by 44
Rapidly progressive Alzheimer's disease and elevated 14-3-3 proteins in cerebrospinal fluid
Jayaratnam, S., Khoo, A., & Basic, D. (2008) · Age and Ageing · doi:10.1093/ageing/afn094 · Cited by 38
Role of HMG-CoA Reductase Inhibitors in Neurological Disorders
Reiss, A. B., & Wirkowski, E. J. (2007) · Drugs · doi:10.2165/00003495-200767150-00001 · Cited by 38
Regulation of the NMDA receptor-mediated synaptic response by acetylcholinesterase inhibitors and its impairment in an animal model of Alzheimer's disease
Chen, G., Chen, P., Tan, H., Ma, D., Dou, F., Feng, J., & Yan, Z. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.04.023 · Cited by 36
Design, Synthesis, and Biological Evaluation of a Novel Class of γ-Secretase Modulators with PPARγ Activity
Hieke, M., Neß, J., Steri, R., Dittrich, M., Greiner, C., Werz, O., Baumann, K., Schubert‐Zsilavecz, M., Weggen, S., & Zettl, H. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm1003073 · Cited by 36
A Small Molecule Inhibitor of Signal Peptide Peptidase Inhibits Plasmodium Development in the Liver and Decreases Malaria Severity
Parvanova, I., Epiphânio, S., Fauq, A. H., Golde, T. E., Prudêncio, M., & Mota, M. M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005078 · Cited by 32
Self-citation
Cognitive Enhancers (Nootropics). Part 2: Drugs Interacting with Enzymes
Froestl, W., Muhs, A., & Pfeifer, A. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121537 · Cited by 31
Promising tacrine/huperzine A‐based dimeric acetylcholinesterase inhibitors for neurodegenerative disorders: From relieving symptoms to modifying diseases through multitarget
Mak, S., Li, W., Fu, H., Luo, J., Cui, W., Hu, S., Pang, Y., Carlier, P. R., Tsim, K. W. K., Pi, R., et al. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15379 · Cited by 30
Validation of Folate in a Convenient Yeast Assay Suited for Identification of Inhibitors of Alzheimer's Amyloid-β Aggregation
Macreadie, I. G., Lotfi-Miri, M., Mohotti, S., Shapira, D. R., Bennett, L. E., & Varghese, J. N. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-15305 · Cited by 29
Molecular Investigations of Protriptyline as a Multi-Target Directed Ligand in Alzheimer's Disease
Bansode, S. B., Jana, A. K., Batkulwar, K., Warkad, S. D., Joshi, R. S., Sengupta, N., & Kulkarni, M. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105196 · Cited by 28
Neuroprotective Potential of Biflavone Ginkgetin: A Review
Çankaya, İ. İ. T., Devkota, H. P., Zengin, G., & Šamec, D. (2023) · Life · doi:10.3390/life13020562 · Cited by 29
Resolution of localized small molecule–Aβ interactions by deep-ultraviolet resonance Raman spectroscopy
Wang, M., & JiJi, R. D. (2011) · Biophysical Chemistry · doi:10.1016/j.bpc.2011.05.017 · Cited by 26
Asymmetric Synthesis of Highly Substituted γ-Amino Acids from Allyltitanium Sulfoximines
Köhler, F., Gais, H., & Raabe, G. (2007) · Organic Letters · doi:10.1021/ol063082q · Cited by 25
Ginseng berry aqueous extract prevents scopolamine‑induced memory impairment in mice
Hu, J., Chun, Y., Kim, J., Cho, I. J., & Ku, S. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.8090 · Cited by 24
Magnetic resonance spectroscopy in vivo of neurochemicals in a transgenic model of Alzheimer's disease: A longitudinal study of metabolites, relaxation time, and behavioral analysis in TASTPM and wild‐type mice
Forster, D. M., Davies, K. E., & Williams, S. R. (2012) · Magnetic Resonance in Medicine · doi:10.1002/mrm.24349 · Cited by 24
Complex Relationships between Substrate Sequence and Sensitivity to Alterations in γ-Secretase Processivity Induced by γ-Secretase Modulators
Jung, J. I., Ran, Y., Cruz, P. E., Rosario, A. M., Ladd, T. B., Kukar, T. L., Koo, E. H., Felsenstein, K. M., & Golde, T. E. (2014) · Biochemistry · doi:10.1021/bi401521t · Cited by 22
Self-citation
Predicting dementia using socio-demographic characteristics and the Free and Cued Selective Reminding Test in the general population
Mura, T., Baramova, M., Gabelle, A., Artéro, S., Dartigues, J., Amieva, H., & Berr, C. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0230-x · Cited by 24
Looking for novel ways to treat the hallmarks of Alzheimer's disease
Stewart, A. J., Fox, A. W., Morimoto, B. H., & Gozes, I. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.8.1183 · Cited by 21
Transcriptome analysis of a tau overexpression model in rats implicates an early pro-inflammatory response
Wang, D. B., Dayton, R. D., Zweig, R. M., & Klein, R. L. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.03.011 · Cited by 21
Present and prospective clinical therapeutic regimens for Alzheimer’s disease
Husain, M. M. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s2012 · Cited by 21
Modulation and Detection of Tau Aggregation with Small-Molecule Ligands
Chang, E. S., Honson, N. S., Bandyopadhyay, B., Funk, K. E., Jensen, J. R., Kim, S., Naphade, S. B., & Kuret, J. (2009) · Current Alzheimer Research · doi:10.2174/156720509789207976 · Cited by 20
Cognitive decline as an outcome and marker of progression toward dementia, in early preventive trials
Mura, T., Coley, N., Amieva, H., Berr, C., Gabelle, A., Ousset, P., Vellas, B., & Andrieu, S. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12431 · Cited by 17
Withdrawal of Antidementia Drugs in Older People: Who, When and How?
Parsons, C. (2016) · Drugs & Aging · doi:10.1007/s40266-016-0384-z · Cited by 20
Neuroimmune Pharmacology of Neurodegenerative and Mental Diseases
Shie, F., Chen, Y., Chen, C., & Ho, I.-K. (2010) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-010-9241-8 · Cited by 19
Alzheimer's disease and related dementias
Hardy, J. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9781139087711.003 · Cited by 18
Aβ oligomer toxicity inhibitor protects memory in models of synaptic toxicity
Scopes, D., O‘Hare, E., Jeggo, R., Whyment, A. D., Spanswick, D. C., Kim, E.-M., Gannon, J., Amijee, H., & Treherne, J. M. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01973.x · Cited by 17
RS-0406 Arrests Amyloid-β Oligomer-Induced Behavioural Deterioration In Vivo
O‘Hare, E., Scopes, D. I. C., Treherne, J. M., Norwood, K., Spanswick, D. C., & Kim, E. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.01.044 · Cited by 17
A review on synthetic inhibitors of dual-specific tyrosine phosphorylation-regulated kinase 1A (DYRK1A) for the treatment of Alzheimer’s disease (AD)
Gehlot, P., Pathak, R., Kumar, S., Choudhary, N. K., & Vyas, V. K. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117925 · Cited by 18
Fluorescence analysis of the action of soluble derivatives of fullerene C60 on amyloid fibrils of the brain peptide Aβ(1–42)
Bobylev, A. G., Marsagishvili, L. G., & Podlubnaya, Z. A. (2010) · BIOPHYSICS · doi:10.1134/s0006350910050027 · Cited by 15
Commonality between Diabetes and Alzheimer's Disease and a New Strategy for the Therapy
Li, L. (2008) · Clinical Medicine Insights Pathology · doi:10.4137/cpath.s667 · Cited by 15
Neuroprotective and neurogenesis agent for treating bipolar II disorder: Add-on memantine to mood stabilizer works
Lu, R., Chen, S., Lee, S.-Y., Chang, Y. H., Chen, S., Chu, C.-H., Tzeng, N., Lee, I. H., Chen, P. S., Yeh, T. L., et al. (2012) · Medical Hypotheses · doi:10.1016/j.mehy.2012.04.042 · Cited by 13
Implication of the Nutritional and Nonnutritional Factors in the Context of Preservation of Cognitive Performance in Patients With Dementia/Depression and Alzheimer Disease
Aliev, G. M., Ashraf, G. M., Kaminsky, Y. G., SHEIKH, I. A., Sudakov, S. K., Yakhno, N. N., Benberin, V. V., & Бачурин, С. О. (2013) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317513504614 · Cited by 14
Event-Related Functional Magnetic Resonance Imaging Changes during Relational Retrieval in Normal Aging and Amnestic Mild Cognitive Impairment
Giovanello, K. S., Brigard, F. D., Ford, J. H., Kaufer, D., Burke, J. R., Browndyke, J. N., & Welsh-Bohmer, K. A. (2012) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617712000689 · Cited by 14
Memantine Potentiates Agonist-Induced Ca2+ Responses in HEK 293 Cells
Blanchard, A. P., Guillemette, G., & Boulay, G. (2008) · Cellular Physiology and Biochemistry · doi:10.1159/000149798 · Cited by 14
Specific recognition of the C-terminal end of Aβ42 by a high affinity monoclonal antibody
Axelsen, T. V., Holm, A., Birkelund, S., Christiansen, G., Ploug, M., & Holm, I. E. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2009.04.007 · Cited by 10
Avoiding Unintended Toxicity
Golde, T. E., & Kukar, T. L. (2009) · Science · doi:10.1126/science.1174267 · Cited by 11
Self-citation
Screening of novel 3α5β-neurosteroids for neuroprotective activity against glutamate- or NMDA-induced excitotoxicity
Šmídková, M., Hájek, M., Adla, S. K., Slavı́ková, B., Chodounská, H., Matoušová, M., Mertlíková‐Kaiserová, H., & Kudová, E. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.03.007 · Cited by 10
Protective effects of Aβ-derived tripeptide, Aβ32–34, on Aβ1–42-induced phosphatidylinositol 4-kinase inhibition and neurotoxicity
Xiong, Z., Kitagawa, K., Nishiuchi, Y., Kimura, T., & Inagaki, C. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.04.022 · Cited by 10
Grapevine Stilbenoids: Bioavailability and Neuroprotection
Waffo‐Téguo, P., Krisa, S., Pawlus, A. D., Richard, T., Monti, J., & Mérillon, J. (2013) · Springer eBooks · doi:10.1007/978-3-642-22144-6_74 · Cited by 11
A synthesis of the γ-secretase inhibitor BMS-708163
Maharvi, G. M., & Fauq, A. H. (2010) · Tetrahedron Letters · doi:10.1016/j.tetlet.2010.10.025 · Cited by 7
Modulation of microglial immune responses by a novel thiourea derivative
Chern, J., Hsu, P.-C., Wang, L., Tsay, H.-J., Kang, I., & Shie, F. (2010) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2010.07.006 · Cited by 4
The roles of GxxxG motif and gamma-secretase components in APP processing
Kim, J. (2009) · Interdisciplinary Bio Central · doi:10.4051/ibc.2009.4.0015 · Cited by 3
Cerliponase alfa decreases Aβ load and alters autophagy- related pathways in mouse hippocampal neurons exposed to fAβ1–42
Köse, S., Çınar, E., Akyel, H., Cakir-Aktas, C., Tel, B. C., Karataş, H., & Kelicen‐Uğur, P. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123105 · Cited by 3
Cognitive screening in patients with diabetes in primary care
Brooke, J. M., & Ojo, O. (2014) · British Journal of Community Nursing · doi:10.12968/bjcn.2014.19.8.401 · Cited by 3
SEN1500, a novel oral amyloid-β aggregation inhibitor, attenuates brain pathology in a mouse model of Alzheimer’s disease
Brunner, D., Flunkert, S., Neddens, J., Duller, S., Scopes, D. I. C., Treherne, J. M., & Hutter‐Paier, B. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.09.028 · Cited by 3
Alzheimer Disease and Dementia
AYDIN, A. C. (2020) · Journal of Literature Pharmacy Sciences · doi:10.5336/pharmsci.2019-71813 · Cited by 3
Approches moléculaires et thérapeutiques de la maladie d’Alzheimer
Hugon, J., & Paquet, C. (2007) · Morphologie · doi:10.1016/j.morpho.2007.10.012 · Cited by 2
Water-Soluble Ginseng Oligosaccharides Prevent Scopolamine-Induced Cholinergic Dysfunction and Inflammatory Cytokine Overexpression
Zeng, T., Zhang, C., Sun, L., & Xu, H. (2025) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-024-01660-8 · Cited by 1
The Role of Apolipoprotein E Concentration and Isoform in Amyloid-beta Metabolism In Vivo
Castellano, J. M. (2011) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/k7416v3s

Authors: Golde, T. E.
Affiliations: Mayo Clinic (US)
Corresponding author: Golde, Todd E.
ORCID: Golde, Todd E.
Venue: Journal of Neurochemistry
Publisher: Wiley
Published: 2006-10-02
Volume: 99
Issue: 3
Pages: 689-707
ISSN: 0022-3042 (ISSN-L)
1471-4159
DOI: 10.1111/j.1471-4159.2006.04211.x
OpenAlex: W2056442085
Cited by: 117
References: 250
Citations by year: 2026: 2 · 2025: 4 · 2024: 3 · 2023: 2 · 2022: 2 · 2021: 2 · 2020: 2 · 2019: 2 · 2018: 1 · 2017: 3 · 2016: 5 · 2015: 3 · 2014: 3 · 2013: 5 · 2012: 6
FWCI: 2.06
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Journal of Neurochemistry (publishedVersion)
PubMed (publishedVersion)
Funders: Alzheimer's Association
National Institutes of Health
National Institute on Aging
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords: Alzheimer's disease, disease-modifying therapy, amyloid-beta, tau protein, acetylcholinesterase inhibitors, memantine, NMDA receptor, neuroprotection, excitotoxicity, therapeutic target, clinical trials, dementia
MeSH terms: Alzheimer Disease, Animals, Humans, Immunotherapy, Peptide Hydrolases, Phosphorylation, Protease Inhibitors, Amyloid beta-Peptides, Neurofibrillary Tangles, tau Proteins, Protein Folding, Molecular Chaperones, Alzheimer Vaccines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Disease modifying therapy for AD?1

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks